首页> 外文期刊>World Journal of Gastroenterology >Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus
【24h】

Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus

机译:抗结核治疗对乙型肝炎病毒感染的肺结核患者肝功能的影响

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To observe the effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients with hepatitis B virus (HBV) infection, and to compare the differences of liver function by two treatments of anti-tuberculosis. METHODS: Forty-seven TB patients with HBV infection and 170 TB patients without HBV infection were divided into HPBE(S) and HLAMKO treatment groups. Liver function tests before and after the treatments were performed once in 2 wk or monthly, and their clinical manifestations were recorded. RESULTS: The rate of hepatotoxicity occurred in 26 (59%) TB patients with HBV during anti-TB treatment, higher than that in 40 (24%) TB patients without HBV. Hepatotoxicity occurred in 66 out of 217 patients, and the incidence of liver dysfunction was 46.1% in HPBE(S) group, significantly higher than that in HLAMKO group (12.7%) (p<0.01). CONCLUSION: TB patients with HBV should choose HLAMKO treatment because of fewer hepatotoxicity.
机译:目的:观察抗结核治疗对乙型肝炎病毒(HBV)感染的肺结核患者肝功能的影响,比较两种抗结核治疗方法对肝功能的影响。方法:将47例HBV感染的TB患者和170例无HBV感染的TB患者分为HPBE(S)和HLAMKO治疗组。每2周或每月进行一次治疗前后的肝功能检查,并记录其临床表现。结果:26例(59%)TB患者在抗结核治疗期间发生了肝毒性,高于40例(24%)无HBV的患者。 217例患者中有66例发生肝毒性,HPBE(S)组的肝功能障碍发生率为46.1%,显着高于HLAMKO组(12.7%)(p <0.01)。结论:TB患者HBV肝毒性较低,应选择HLAMKO治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号